Long-lasting HIV prevention drug could be game changer — but who will pay?

T.V. Padma

Nature, 2022, vol. 608, issue 7923, 460-461

Abstract: Injectable antiviral cabotegravir provides stronger protection than oral pill, but researchers fear it could be too expensive to make a difference for countries with the greatest disease burden.

Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/d41586-022-02123-x Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:608:y:2022:i:7923:d:10.1038_d41586-022-02123-x

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/d41586-022-02123-x

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().